These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

287 related articles for article (PubMed ID: 36054476)

  • 1. Characterization of pathogen-inactivated COVID-19 convalescent plasma and responses in transfused patients.
    Weisser M; Khanna N; Hedstueck A; Sutter ST; Roesch S; Stehle G; Sava M; Deigendesch N; Battegay M; Infanti L; Holbro A; Bassetti S; Pargger H; Hirsch HH; Leuzinger K; Kaiser L; Vu DL; Baur K; Massaro N; Busch MP; Simmons G; Stone M; Felgner PL; de Assis RR; Khan S; Tsai CT; Robinson PV; Seftel D; Irsch J; Bagri A; Buser AS; Corash L
    Transfusion; 2022 Oct; 62(10):1997-2011. PubMed ID: 36054476
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Use of Outpatient-Derived COVID-19 Convalescent Plasma in COVID-19 Patients Before Seroconversion.
    Wirz OF; Röltgen K; Stevens BA; Pandey S; Sahoo MK; Tolentino L; Verghese M; Nguyen K; Hunter M; Snow TT; Singh AR; Blish CA; Cochran JR; Zehnder JL; Nadeau KC; Pinsky BA; Pham TD; Boyd SD
    Front Immunol; 2021; 12():739037. PubMed ID: 34594341
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Severe Acute Respiratory Syndrome Coronavirus 2 Neutralizing Antibody Titers in Convalescent Plasma and Recipients in New Mexico: An Open Treatment Study in Patients With Coronavirus Disease 2019.
    Bradfute SB; Hurwitz I; Yingling AV; Ye C; Cheng Q; Noonan TP; Raval JS; Sosa NR; Mertz GJ; Perkins DJ; Harkins MS
    J Infect Dis; 2020 Oct; 222(10):1620-1628. PubMed ID: 32779705
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antibody profiles in COVID-19 convalescent plasma prepared with amotosalen/UVA pathogen reduction treatment.
    Bagri A; de Assis RR; Tsai CT; Simmons G; Mei ZW; Von Goetz M; Gatmaitan M; Stone M; Di Germanio C; Martinelli R; Darst O; Rioveros J; Robinson PV; Ward D; Ziman A; Seftel D; Khan S; Busch MP; Felgner PL; Corash LM
    Transfusion; 2022 Mar; 62(3):570-583. PubMed ID: 35128658
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment of 5 Critically Ill Patients With COVID-19 With Convalescent Plasma.
    Shen C; Wang Z; Zhao F; Yang Y; Li J; Yuan J; Wang F; Li D; Yang M; Xing L; Wei J; Xiao H; Yang Y; Qu J; Qing L; Chen L; Xu Z; Peng L; Li Y; Zheng H; Chen F; Huang K; Jiang Y; Liu D; Zhang Z; Liu Y; Liu L
    JAMA; 2020 Apr; 323(16):1582-1589. PubMed ID: 32219428
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Randomized clinical trial to evaluate safety and efficacy of convalescent plasma use among hospitalized patients with COVID-19 (PERUCONPLASMA): a structured summary of a study protocol for a randomized controlled trial.
    Soto A; Krapp F; Vargas A; Cabrejos L; Argumanis E; García PL; Altamirano K; Montes M; Chacón-Uscamaita PR; García PJ
    Trials; 2021 May; 22(1):342. PubMed ID: 34001174
    [TBL] [Abstract][Full Text] [Related]  

  • 7. COVID-19 convalescent plasma cohort study: Evaluation of the association between both donor and recipient neutralizing antibody titers and patient outcomes.
    Yokoyama APH; Wendel S; Bonet-Bub C; Fachini RM; Dametto APF; Blumm F; Dutra VF; Candelaria GTP; Sakashita AM; Machado RRG; Fontão-Wendel R; Hamerschlak N; Achkar R; Assunção MSC; Scuracchio P; Nudelman V; Pastore L; Pinho JRR; Ben MD; Filho RK; Marra AR; Amano MT; Kallás EG; Helito AS; de Carvalho CRR; Araujo DB; Durigon EL; Camargo AA; Rizzo LV; Reis LFL; Kutner JM
    Transfusion; 2021 Aug; 61(8):2295-2306. PubMed ID: 34173248
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacokinetics of high-titer anti-SARS-CoV-2 human convalescent plasma in high-risk children.
    Gordon O; Brosnan MK; Yoon S; Jung D; Littlefield K; Ganesan A; Caputo CA; Li M; Morgenlander WR; Henson SN; Ordonez AA; De Jesus P; Tucker EW; Peart Akindele N; Ma Z; Wilson J; Ruiz-Bedoya CA; Younger MEM; Bloch EM; Shoham S; Sullivan D; Tobian AA; Cooke KR; Larman B; Gobburu JV; Casadevall A; Pekosz A; Lederman HM; Klein SL; Jain SK
    JCI Insight; 2022 Jan; 7(2):. PubMed ID: 34855624
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Distinct SARS-CoV-2 antibody reactivity patterns in coronavirus convalescent plasma revealed by a coronavirus antigen microarray.
    Assis R; Jain A; Nakajima R; Jasinskas A; Khan S; Davies H; Corash L; Dumont LJ; Kelly K; Simmons G; Stone M; Di Germanio C; Busch M; Felgner PL
    Sci Rep; 2021 Apr; 11(1):7554. PubMed ID: 33824382
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Outcomes of Convalescent Plasma with Defined High versus Lower Neutralizing Antibody Titers against SARS-CoV-2 among Hospitalized Patients: CoronaVirus Inactivating Plasma (CoVIP) Study.
    Bartelt LA; Markmann AJ; Nelson B; Keys J; Root H; Henderson HI; Kuruc J; Baker C; Bhowmik DR; Hou YJ; Premkumar L; Cornaby C; Schmitz JL; Weiss S; Park Y; Baric R; de Silva AM; Lachiewicz A; Napravnik S; van Duin D; Margolis DM
    mBio; 2022 Oct; 13(5):e0175122. PubMed ID: 36135380
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluating the efficacy and safety of human anti-SARS-CoV-2 convalescent plasma in severely ill adults with COVID-19: A structured summary of a study protocol for a randomized controlled trial.
    Eckhardt CM; Cummings MJ; Rajagopalan KN; Borden S; Bitan ZC; Wolf A; Kantor A; Briese T; Meyer BJ; Jacobson SD; Scotto D; Mishra N; Philip NM; Stotler BA; Schwartz J; Shaz B; Spitalnik SL; Eisenberger A; Hod EA; Justman J; Cheung K; Lipkin WI; O'Donnell MR
    Trials; 2020 Jun; 21(1):499. PubMed ID: 32513308
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Preservation of anti-SARS-CoV-2 neutralising antibodies in convalescent plasma after pathogen reduction with methylene blue and visible light.
    Larrea L; Castro E; Navarro L; Vera B; Francés-Gómez C; Sánchez-Sendra B; Giménez Á; Castelló E; Collado M; Vayá MJ; Mirabet V; Callao V; Ortiz-de-Salazar MI; Roig R; Geller R; Arbona C
    Blood Transfus; 2022 May; 20(3):206-212. PubMed ID: 34369870
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Kinetics of Nucleocapsid, Spike and Neutralizing Antibodies, and Viral Load in Patients with Severe COVID-19 Treated with Convalescent Plasma.
    Thomopoulos TP; Rosati M; Terpos E; Stellas D; Hu X; Karaliota S; Bouchla A; Katagas I; Antoniadou A; Mentis A; Papageorgiou SG; Politou M; Bear J; Donohue D; Kotanidou A; Kalomenidis I; Korompoki E; Burns R; Pagoni M; Grouzi E; Labropoulou S; Stamoulis K; Bamias A; Tsiodras S; Dimopoulos MA; Pavlakis GN; Pappa V; Felber BK
    Viruses; 2021 Sep; 13(9):. PubMed ID: 34578426
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Preservation of neutralizing antibody function in COVID-19 convalescent plasma treated using a riboflavin and ultraviolet light-based pathogen reduction technology.
    Yonemura S; Hartson L; Dutt TS; Henao-Tamayo M; Goodrich R; Marschner S
    Vox Sang; 2021 Nov; 116(10):1076-1083. PubMed ID: 33835489
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Highly Neutralizing COVID-19 Convalescent Plasmas Potently Block SARS-CoV-2 Replication and Pneumonia in Syrian Hamsters.
    Takamatsu Y; Imai M; Maeda K; Nakajima N; Higashi-Kuwata N; Iwatsuki-Horimoto K; Ito M; Kiso M; Maemura T; Takeda Y; Omata K; Suzuki T; Kawaoka Y; Mitsuya H
    J Virol; 2022 Feb; 96(4):e0155121. PubMed ID: 34818068
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Kinetics of SARS-CoV-2 antibody responses pre-COVID-19 and post-COVID-19 convalescent plasma transfusion in patients with severe respiratory failure: an observational case-control study.
    Klein MN; Wang EW; Zimand P; Beauchamp H; Donis C; Ward MD; Martinez-Hernandez A; Tabatabai A; Baddley JW; Bloch EM; Mullins KE; Fontaine MJ
    J Clin Pathol; 2022 Aug; 75(8):564-571. PubMed ID: 33893156
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Disease Severity, Fever, Age, and Sex Correlate With SARS-CoV-2 Neutralizing Antibody Responses.
    Schlickeiser S; Schwarz T; Steiner S; Wittke K; Al Besher N; Meyer O; Kalus U; Pruß A; Kurth F; Zoller T; Witzenrath M; Sander LE; Müller MA; Scheibenbogen C; Volk HD; Drosten C; Corman VM; Hanitsch LG
    Front Immunol; 2020; 11():628971. PubMed ID: 33584731
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Selecting COVID-19 convalescent plasma for neutralizing antibody potency using a high-capacity SARS-CoV-2 antibody assay.
    Goodhue Meyer E; Simmons G; Grebe E; Gannett M; Franz S; Darst O; Di Germanio C; Stone M; Contestable P; Prichard A; Reik R; Vassallo R; Young P; Busch MP; Williamson P; Dumont LJ
    Transfusion; 2021 Apr; 61(4):1160-1170. PubMed ID: 33554362
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Reconvalescent plasma/camostat mesylate in early SARS-CoV-2 Q-PCR positive high-risk individuals (RES-Q-HR): a structured summary of a study protocol for a randomized controlled trial.
    Keitel V; Jensen B; Feldt T; Fischer JC; Bode JG; Matuschek C; Bölke E; Budach W; Plettenberg C; Scheckenbach K; Kindgen-Milles D; Timm J; Müller L; Kolbe H; Stöhr A; Calles C; Hippe A; Verde P; Spinner CD; Schneider J; Wolf T; Kern WV; Nattermann J; Zoufaly A; Ohmann C; Luedde T;
    Trials; 2021 May; 22(1):343. PubMed ID: 34001215
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Convalescent plasma treatment of critically ill intensive care COVID-19 patients.
    Lindemann M; Lenz V; Knop D; Klump H; Alt M; Aufderhorst UW; Schipper L; Schwarzkopf S; Meller L; Steckel N; Koldehoff M; Heinold A; Heinemann FM; Fischer J; Hutschenreuter G; Knabbe C; Dolff S; Brenner T; Dittmer U; Witzke O; Herbstreit F; Horn PA; Krawczyk A
    Transfusion; 2021 May; 61(5):1394-1403. PubMed ID: 33784412
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.